



Recipient Information 1. Recipient Name THE UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH 3500 CAMP BOWIE BLVD FORT WORTH, TX 76107 2. Congressional District of Recipient 12 3. Payment System Identifier (ID) 1756064033A1 4. Employer Identification Number (EIN) 756064033 5. Data Universal Numbering System (DUNS) 110091808 6. Recipient's Unique Entity Identifier JE8AKPCR2KA4 7. Project Director or Principal Investigator Daniel Eric Burgard, MLS daniel.burgard@unthsc.edu 817-735-2589 8. Authorized Official Kristina Marie Smith kristina.smith@unthsc.edu 817-735-5073	Federal Award Information 11. Award Number 5UG4LM012345-10 12. Unique Federal Award Identification Number (FAIN) UG4LM012345 13. Statutory Authority 42 USC 286b-2, 286b-6 42 CFR 59a 14. Federal Award Project Title Regional Medical Library for Region 3 of the Network of the National Library of Medicine (AR, KS, LA, MO, NE, OK, TX) and National Public Health Coordination Office 15. Assistance Listing Number 93.879 16. Assistance Listing Program Title Medical Library Assistance 17. Award Action Type Non-Competing Continuation 18. Is the Award R&D? Yes																										
Federal Agency Information 9. Awarding Agency Contact Information Amy Keener NATIONAL LIBRARY OF MEDICINE akeener@mail.nih.gov 301-496-6131 10. Program Official Contact Information Sung Sug Yoon Hsa-program Officer NATIONAL LIBRARY OF MEDICINE sungsug.yoon@nih.gov (301) 402-6959	<table border="1"> <tr> <th colspan="2" style="background-color: #e0f0ff;">Summary Federal Award Financial Information</th> </tr> <tr> <td colspan="2" style="background-color: #e0f0ff;">19. Budget Period Start Date 05/01/2025 – End Date 04/30/2026</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$1,178,770</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$907,196</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$271,574</td> </tr> <tr> <td>21. Authorized Carryover</td> <td></td> </tr> <tr> <td>22. Offset</td> <td></td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$1,178,770</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$1,178,770</td> </tr> <tr> <td colspan="2" style="border-top: 1px dashed black;"></td> </tr> <tr> <td colspan="2" style="background-color: #e0f0ff;">26. Project Period Start Date 05/01/2016 – End Date 04/30/2026</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$4,993,315</td> </tr> </table> 28. Authorized Treatment of Program Income Additional Costs 29. Grants Management Officer - Signature Andrea Culhane	Summary Federal Award Financial Information		19. Budget Period Start Date 05/01/2025 – End Date 04/30/2026		20. Total Amount of Federal Funds Obligated by this Action	\$1,178,770	20 a. Direct Cost Amount	\$907,196	20 b. Indirect Cost Amount	\$271,574	21. Authorized Carryover		22. Offset		23. Total Amount of Federal Funds Obligated this budget period	\$1,178,770	24. Total Approved Cost Sharing or Matching, where applicable	\$0	25. Total Federal and Non-Federal Approved this Budget Period	\$1,178,770			26. Project Period Start Date 05/01/2016 – End Date 04/30/2026		27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$4,993,315
Summary Federal Award Financial Information																											
19. Budget Period Start Date 05/01/2025 – End Date 04/30/2026																											
20. Total Amount of Federal Funds Obligated by this Action	\$1,178,770																										
20 a. Direct Cost Amount	\$907,196																										
20 b. Indirect Cost Amount	\$271,574																										
21. Authorized Carryover																											
22. Offset																											
23. Total Amount of Federal Funds Obligated this budget period	\$1,178,770																										
24. Total Approved Cost Sharing or Matching, where applicable	\$0																										
25. Total Federal and Non-Federal Approved this Budget Period	\$1,178,770																										
26. Project Period Start Date 05/01/2016 – End Date 04/30/2026																											
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$4,993,315																										
30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.																											



National Network of Libraries of Medicine
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL LIBRARY OF MEDICINE

SECTION I – AWARD DATA – 5UG4LM012345-10

Principal Investigator(s):

Daniel Eric Burgard, MLS

Award e-mailed to: ospext@unthsc.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$1,178,770 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NORTH TEXAS HLTH SCI CTR in support of the above referenced project. This award is pursuant to the authority of 42 USC 286b-2, 286b-6 42 CFR 59a and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Library Of Medicine of the National Institutes of Health under Award Number UG4LM012345. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Andrea Culhane
Grants Management Officer
NATIONAL LIBRARY OF MEDICINE

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)
Salaries and Wages

\$479,723

Fringe Benefits	\$153,512
Personnel Costs (Subtotal)	\$633,235
Materials & Supplies	\$2,314
Travel	\$25,200
Other	\$138,000
Subawards/Consortium/Contractual Costs	\$108,447
Federal Direct Costs	\$907,196
Federal F&A Costs	\$271,574
Approved Budget	\$1,178,770
Total Amount of Federal Funds Authorized (Federal Share)	\$1,178,770
TOTAL FEDERAL AWARD AMOUNT	\$1,178,770
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$1,178,770

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
10	\$1,178,770	\$1,178,770

Fiscal Information:

Payment System Identifier: 1756064033A1
Document Number: ULM012345B
PMS Account Type: P (Subaccount)
Fiscal Year: 2025

IC	CAN	2025
LM	8023879	\$1,178,770

NIH Administrative Data:

PCC: MRMLIS / OC: 41029 / Released: 06/20/2025
Award Processed: 06/27/2025 11:33:14 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5UG4LM012345-10

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 5UG4LM012345-10

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-

research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UG4LM012345. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the Payment Management System (PMS) within 120 days of the period of performance end date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#gps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the real-time cash drawdown data in PMS. NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16, K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL5, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

Unless an application for competitive renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted by that date as well. Instructions for preparing an Interim or Final RPPR are at:

https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim or Final RPPR. *Note that data reported within Section I of the Interim and Final RPPR forms will be made public and should be written for a lay person audience.*

NIH requires electronic submission of the final invention statement through the Closeout feature in the Commons.

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final RPPR is not required. However, a final expenditure FFR is required and must be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

Recipients must administer the project in compliance with federal civil rights laws that prohibit

discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

Recipient is compliant with Title IX of the Education Amendments of 1972, as amended, 20 U.S.C. §§ 1681 et seq., including the requirements set forth in Presidential Executive Order 14168 titled Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government, and Title VI of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000d et seq., and Recipient will remain compliant for the duration of the Agreement.

- The above requirements are conditions of payment that go the essence of the Agreement and are therefore material terms of the Agreement.
- Payments under the Agreement are predicated on compliance with the above requirements, and therefore Recipient is not eligible for funding under the Agreement or to retain any funding under the Agreement absent compliance with the above requirements.
- Recipient acknowledges that this certification reflects a change in the government's position regarding the materiality of the foregoing requirements and therefore any prior payment of similar claims does not reflect the materiality of the foregoing requirements to this Agreement.
- Recipient acknowledges that a knowing false statement relating to Recipient's compliance with the above requirements and/or eligibility for the Agreement may subject Recipient to liability under the False Claims Act, 31 U.S.C. § 3729, and/or criminal liability, including under 18 U.S.C. §§ 287 and 1001.

SECTION IV – LM SPECIFIC AWARD CONDITIONS – 5UG4LM012345-10

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

NIH and the recipient have renegotiated the scope of this award. Pursuant to the revised scope, NIH funds may only be used to support activities within the revised scope of the award. NIH funds may not be used to support activities that are outside the revised scope of the award, including diversity, equity, and inclusion (DEI) research or related research training activities or programs. Any funds used to support activities outside the scope will result in a disallowance of costs, and funds will be recovered.

This term is consistent with NIH's ongoing internal review of NIH's priorities and the alignment of awards with those priorities as well as a review of program integrity of awards. Such review includes, but is not limited to, a review for fraud, waste and abuse, and a review of the NIH portfolio to determine whether awards are in the best interests of the government and consistent with policy priorities. If recipients are unclear on whether a specific activity constitutes diversity, equity, and inclusion (DEI) or has questions regarding other activities that could be considered outside the scope of the award, refrain from drawing down funds and consult with the funding IC, particularly where the activity may impact the specific aims, goals, and objectives of the project.

REVISED AIMS

This award approves the revised aims as submitted in the document dated 06/02/25 from Caroline Sheehan / University of North Texas Health Science Center.

RESTRICTION: HUMAN SUBJECTS RESEARCH

This award is not approved for performance of human subjects research. If the awardee proposes to add any new human subjects research under this award in the future, NLM prior approval is required before initiating human subjects research. The following information must be submitted to and accepted by the NLM Grants Management Officer prior to initiating any human subjects research at any site under this award:

- Certification of IRB approval and/or exemption status determination, as appropriate. The IRB approval/determination must be sent by an authorized organizational representative (AOR), via email, to the NLM grants management specialist and NLM program official listed on this Notice of Award.
- Completed human subjects study record in the NIH Human Subjects System (HSS) module.
- Certification that all key personnel have completed education on the protection of human subjects, in accordance with NIH policy, "Required Education in the Protection of Human Research Participants," found here: <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html>.

No funds may be drawn down from the payment system and no obligations may be made against NIH funds for any research involving human subjects by any site engaged in such research until the above requirements have been met and approval has been issued in writing from the NLM Grants Management Officer.

PRIOR APPROVAL OF DELAYED ONSET RESEARCH INVOLVING HUMAN SUBJECTS

Requests for prior approval of planned research involving human subjects must be submitted to NLM/EP no later than 30 days before the proposed implementation of research involving human subjects, including a completed study record in NIH eRA Human Subjects System (HSS).

RESTRICTION: OUTREACH PROGRAM SUBAWARDS

Funds awarded in the amount of \$154,770 total costs (\$115,500 direct costs + \$39,270 F&A) for future outreach subawards are restricted and may not be used for any other purpose without prior written approval from the NLM. A list of all competitive subawards funded (including sub awardee name, amount of subaward, purpose of subaward) during this budget period must be reported as part of the annual Research Performance Progress Report (RPPR). Competitive subawards are funded for a one-year period only, with an option to renew based on demonstrated adequate performance and continuing need. The awardee is responsible for ensuring that each funded consortium submits performance and evaluation data to the NLM data repositories according to the policies developed by the NNSC and NLM. ***Any subaward that will result in the award of \$50,000 or more to a single organization in one project year, or that will involve human subjects research, requires written prior approval from the NLM Grants Management Officer.***

REQUIREMENT: FEDERAL FINANCIAL REPORT (FFR)

As of January 1, 2021, all Federal Financial Reports (FFRs) must be submitted via the Payment Management System (PMS) <https://pms.psc.gov/>. See <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-046.html> for additional information. The Federal Financial Report must be submitted no later than 90 days after the end of the calendar quarter in which the budget period ended.

REQUIREMENT: KEY PERSONNEL EFFORT

In addition to the PI, any absence, replacement, or substantial reduction in effort of the following individual(s) named below, requires written prior approval from the National Library of Medicine:

Brian Leaf - 12 calendar months effort.

REQUIREMENT: PROGRAM REPORTING

Follow the instructions located at <https://nnlm.atlassian.net/wiki/spaces/OPS/pages/2530508801/UG4+Reporting+Requirements> complete the required reports for the NNLM.

REQUIREMENT: PUBLICATION AND COPYRIGHTING, DATA SHARING

Per Section 8.2.1. - Right in Data (Publication and Copyrighting) of the NIH Grants Policy Statement, the NIH must be given a royalty-free, nonexclusive, and irrevocable license for the Federal government to reproduce, publish, or otherwise use the material and to authorize others to do so for Federal purposes, i.e. the ongoing development of the National Network of Libraries of Medicine. Data developed by a consortium participant is also subject to this policy. NLM requires the dissemination of knowledge and information associated with this cooperative agreement, and as part of the awardee's Data Sharing Plan, this information must be submitted to the following collection sites:

- Network of the National Library of Medicine (NNLM): <https://nnlm.gov>
- Medical Library Association (MLA) Educational Clearinghouse if applicable
- Other site specifically designated by the NLM as part of the Network of the National Library of Medicine (considering changes in the project and data repositories required to maintain sharing within the Network)

REQUIREMENT: NIH ACKNOWLEDGEMENT

Developed resources related to this project must include an acknowledgment of NIH grant support and a disclaimer stating the following: "Developed resources reported in this [publications, press releases, internet sites] are supported by the National Library of Medicine (NLM), National Institutes of Health (NIH) under cooperative agreement number **UG4LM012345**. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

If the recipient plans to issue a press release about research supported by an NIH grant, it should notify the NIH funding component in advance to allow for coordination. For media contact information, see: http://www.nih.gov/news/media_contacts.htm.

NOTICE OF FUNDING OPPORTUNITY (NOFO)

This award is subject to the conditions set forth in NOFO Number RFA-LM-20-001, which are incorporated by reference as special Terms and Conditions of this award. This NOFO may be accessed at: <https://grants.nih.gov/grants/guide/rfa-files/RFA-LM-20-001.html>.

AWARDED BUDGET

The requested budget in the Year -10 RPPR was reviewed and determined not to represent significant re-budgeting. Therefore, the awarded costs provided are consistent with the previously committed level.

PROFESSIONAL DEVELOPMENT COSTS

Any and all costs for Professional Development are unallowable and no funds from this award may be expended for these purposes.

CONSORTIUM/CONTRACTUAL COSTS

This award includes funds for consortium activity with:

University of Kansas Medical Center - \$111,785 total costs (\$83,734 direct costs + \$28,001 indirect costs)

Each consortium is to be established and administered in accordance with the NIH Grants Policy Statement. No foreign performance site may be added to this project without prior written approval from the National Library of Medicine.

INFORMATION: PRIOR APPROVAL REQUESTS

Prior approval requests for changes to PI/PI or Key Personnel named in the Notice of Award (NoA), Carryover Requests, or No-cost Extensions should be submitted electronically via the eRA Commons [Prior Approval Module](#). All other prior approval requests may be submitted via email directly to the Grants Management Specialist and Program Official named on this Notice of Award. All requests for NLM prior approval must be made no less than 30 days before the proposed change and submitted by the AOR/SO.

Please refer to Part II Chapter 8 of the NIH Grants Policy Statement for the activities and/or expenditures that require NIH prior approval: https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.1_changes_in_project_and_budget.htm.

COOPERATIVE AGREEMENT TERMS AND CONDITIONS OF AWARD

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an

"assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.

The PD(s)/PI(s) Primary Responsibilities

The PD/PI will agree to accept the close coordination, cooperation, and participation of the NLM staff (Project Scientists (PS), Project Coordinator (PC), Program Official (PO) and other appropriate NLM staff) in those aspects of program and technical management of the project as described below. Specifically, the PD/PI supported by the Cooperative Agreement will:

- Retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.
- Assess and evaluate project and program activities in accordance with applicable guidance in the [NNLM guidelines](#) and procedures documents.
- Ensure publications and presentations of work performed under this Cooperative Agreement have appropriate acknowledgement of NLM support. Timely publication of major findings is encouraged.
- Provide, in addition to standard annual progress reports, other relevant information to the NNLM PS(s), PC, or PO and coordinate and cooperate with OET staff, and other members of appropriate collaborating NLM programs.
- Work directly with the PS(s) and PC on the coordination of NNLM program activities and the integration of individual projects within the NNLM as well as with other relevant NLM programs.
- Participate in meetings, work groups, and training as needed to plan and accomplish the goals of the NNLM.
- Actively participate as a voting member of the NNLM Steering Committee.
- Accept and implement all procedural and policy decisions approved by the Steering Committee (SC) in addition to applicable NIH policies, laws, and regulations.

NIH program staff provides scientific technical assistance and advice to recipients of cooperative agreements during the conduct of an activity, above and beyond the levels required normally for program stewardship of grants, but without dominating the relationship as described below.

Project Scientist (PS) Responsibilities

One or more designated NLM staff members, acting as Project Scientist (PS), will have substantial programmatic involvement. The role of the PS will be to facilitate and not to direct. This includes facilitating the partnership and collaboration between NNLM RMLs, Offices and Centers, national partners, and NLM. The PS role includes helping to maintain the overall balance in the program commensurate with the functions and scope of the program's activities, facilitating communication and coordination, and ensuring that the activities of the awardees are consistent with the mission of the NNLM. Specifically, the NLM Project Scientist(s):

- Cooperate or coordinate with, or provide assistance to, awardees in performing project activities, e.g., development of projects; data collection, analyses, and interpretation; and re-establishment of objectives during the course of a project;
- Provide for an option to halt a project activity if technical performance requirements are not met or if program objectives have already been met;
- Specify under the terms and conditions of award that the project be structured in stages and that NIH staff review and approve each stage before work may begin on such stage;
- Provide technical monitoring to permit specific direction of the project, including recommending approval of changes in approaches;
- Participate on the Steering Committee (SC) as a nonvoting member as needed (the chairperson will be someone other than an NLM staff member) or in other functions responsible for helping to guide the course of long-term projects or activities; and
- Participate in the presentation of research results, including publications from the project.

Project Coordinator (PC) Responsibilities

The Project Coordinator will work in partnership with awardees, PSs and the PO to help coordinate activities and resources across the NNLM program to ensure effective and efficient performance of the aims and mission of the NNLM.

- Cooperation or coordination with, or assistance to, awardees in performing project activities, e.g., coordination of program networks; providing access to NIH supported resources; identifying other participants/resources for the project;
- Participate on committees as a voting member (the chairperson will be someone other than an NLM staff member) or in other functions responsible for helping to guide the course of long-term projects or

activities, e.g., annual meetings of awardees, Chair and/or member of project oversight committees composed of NIH officials.

Program Official (PO) Responsibilities

The PO is the NIH official responsible for the programmatic, scientific, and/or technical aspects of the award that provides normal program stewardship of the award. The PO will have access to data generated under this Cooperative Agreement and may periodically review the data and progress reports. The PO may use information obtained from the data for the preparation of internal and external reports on the activities of the project. The PO will work in partnership with the PC and PSs in regard to providing technical assistance to the NNLM. Normal PO stewardship includes:

- Enforcement of general statutory, regulatory, or policy requirements;
- Approval of awardee plans prior to award and review of performance after completion;
- Programmatic review of prior approval requests;
- Evaluation of progress by reviews of technical or fiscal reports, site visits, or external consultants, to determine that performance is consistent with the terms and conditions of the award;
- Technical assistance requested by awardees, or unanticipated procedures to correct programmatic or financial deficiencies in awardees' performance;
- Scientific/technical discussions with awardees, or actions to facilitate or expedite interactions between awardees, e.g., organizing and holding meetings of investigators.

Areas of Joint Responsibility include:

The PD/PIs of the NNLM RMLs, Offices and Centers, and the PSs and PC will be jointly responsible for the coordination and collaboration of NNLM activities and the integration of individual projects with other appropriate NLM programs. Joint responsibilities include:

- Developing collaborative working groups to reduce duplication of effort and maximizing efficiencies.
- Organizing and conducting regular meetings to share progress and foster collaborations within NNLM, by teleconference, virtual meeting, or face-to-face, as needed.
- Developing and implementing strategies for evaluating and reporting the effectiveness of the NNLM.

Steering Committee (SC)

The Steering Committee (SC) will provide overall integration among NNLM RMLs, Offices and Centers, and network partners. It will also serve as an interface between the individual projects funded under this FOA and appropriate NLM programs. The SC will consist of the PD/PI for each NNLM RML, heads of the Offices and Centers, and the PC. The PSs and the PO will be nonvoting members. When appropriate, the SC may include representatives from outside working groups and NLM staff who will be nonvoting members. The SC Chair will be elected from among the NNLM voting members but may not be an NLM or NIH staff member. Additional information about the NNLM and current procedures is available in the [NNLM Workbook](#).

Dispute Resolution

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

Project Scientist Contact Information:

Email: NNLM-PS@LIST.NIH.GOV Phone: 301-496-4777

SPREADSHEET SUMMARY

AWARD NUMBER: 5UG4LM012345-10

INSTITUTION: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR

Budget	Year 10
Salaries and Wages	\$479,723
Fringe Benefits	\$153,512
Personnel Costs (Subtotal)	\$633,235
Materials & Supplies	\$2,314
Travel	\$25,200

Other	\$138,000
Subawards/Consortium/Contractual Costs	\$108,447
TOTAL FEDERAL DC	\$907,196
TOTAL FEDERAL F&A	\$271,574
TOTAL COST	\$1,178,770

Facilities and Administrative Costs	Year 10
F&A Cost Rate 1	34%
F&A Cost Base 1	\$798,748
F&A Costs 1	\$271,574